Abstract
We report the first known instance of the clinical use of 99mTc-mebrofenin hepatobiliary scintigraphy (HBS) for the optimization of radiotherapy treatment planning and for the follow-up of acute toxicity in a patient undergoing stereotactic body radiation therapy for hepatocellular carcinoma. In our experience, HBS allowed the identification and the sparing of more functioning liver areas, thus potentially reducing the risk of radiation-induced liver toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | e21-e24 |
| Journal | Tumori |
| Volume | 102 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Sept 2016 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hepatocellular carcinoma
- Liver cancer
- Stereotactic body radiation therapy (SBRT)
- Tc-mebrofenin hepatobiliary scintigraphy (HBS)
- Toxicity
Fingerprint
Dive into the research topics of 'Role of functional imaging in treatment plan optimization of stereotactic body radiation therapy for liver cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver